Rhelion Life Sciences (STU:4YX0) Total Equity: €7.07 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rhelion Life Sciences Total Equity?

Rhelion Life Sciences STU:4YX0 Total Equity is €7.07 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Rhelion Life Sciences's total equity for the quarter that ended in Mar. 2026 was €7.07 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Rhelion Life Sciences Total Equity Historical Data

* Premium members only.

The historical data trend for Rhelion Life Sciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhelion Life Sciences Total Equity Chart

Rhelion Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial 20.91 17.98 13.77 11.18 7.07

Rhelion Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.18 10.61 9.62 9.05 7.07

Rhelion Life Sciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Rhelion Life Sciences's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=9.186-2.111
=7.08

Rhelion Life Sciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=9.186-2.111
=7.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €7.07 Mil mean?
Rhelion Life Sciences (STU:4YX0) has a Total Equity of €7.07 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Rhelion Life Sciences and its competitors.
Is Rhelion Life Sciences' Total Equity too high?
Rhelion Life Sciences' current Total Equity is €7.07 Mil.
How does Rhelion Life Sciences' Total Equity compare to ZTS?
Rhelion Life Sciences' Total Equity of €7.07 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Rhelion Life Sciences and its competitors. Rhelion Life Sciences's current Total Equity is €7.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (STU:4YX0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current Total Equity is €7.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Rhelion Life Sciences (STU:4YX0), the current Total Equity is €7.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhelion Life Sciences Business Description

Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.